β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

Summary

This study is a prospective, randomized controlled study on nutritional support and metabolic regulation. It assesses the safety, compliance, and improvement of metabolic/physical-related indicators when using β-alanine within the specified dose range as dietary supplementation, in addition to the standard first-line treatment. The anti-tumor efficacy (ORR, PFS, OS) is the exploratory endpoint.

Timeline

Start

2025-12-24

Primary completion

2028-12-05

Completion

2030-12-05

Drugs

Indications